QURE vs UNH

uniQure's previous 10x potential, primarily tied to AMT-130 for Huntington's disease, has been severely hampered by recent developments. The FDA's criticism of the study design, requiring additional studies and delaying the BLA submission, coupled with multiple securities class-action lawsuits, represents a significant setback. While the long-term market opportunity for gene therapy in rare diseas...

UnitedHealth Group (UNH) remains a healthcare titan, but its sheer scale and the highly regulated nature of its operations fundamentally limit its 10x growth potential within 3-5 years. The recent Optum Health operating loss of $278M in 2025 (compared to $7.77B income in 2024) is a significant concern, eroding the growth narrative that Optum once provided. Furthermore, the proposed 0.09% Medicare ...